LAUSR

This double‐blind randomized clinical trial aimed to investigate impact of Cornus mas L. fruit extract (CMFE) on liver function in nonalcoholic fatty liver disease (NAFLD). Fifty patients were randomly assigned into the CMFE and placebo groups to receive 20 ml of the extract or placebo for 12 weeks, respectively. Serum alanine aminotransferase, aspartate aminotransferase, cytokeratin 18 (CK‐18) levels, and steatosis and fibrosis scores were examined before and after the intervention. Although, a significant decrease was observed in CK‐18 levels among the CMFE group (288.80 ± 85.40 vs. 235.66 ± 60.38; p = .001) after 12 weeks, no significant difference was found between the two groups. Moreover, a significant increase in fibrosis score in the placebo group (8.20 (6.35–9.40) vs. 8.40 (7.70–13.00); p = .03) as well as a significant difference in this marker (CMEF: 7.64 (6.30–8.25); placebo: 8.40 (7.70–13.00); p = .02) and its changes (CMEF: 0.60 (−1.00–1.07); placebo: 0.80 (−0.25–3.95); p = .02) were found between the groups after 12 weeks. No significant effect was noted on other variables. Therefore, consuming CMFE might have some beneficial effects on liver function markers in NAFLD. However, more studies are required in this area.